Stuart A. Arbuckle

2016

In 2016, Stuart A. Arbuckle earned a total compensation of $5.6M as EVP & Chief Commercial Officer at Vertex Pharmaceuticals, a 37% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$420,000
Option Awards$1,305,144
Salary$672,885
Stock Awards$3,150,148
Other$12,885
Total$5,561,062

Arbuckle received $3.2M in stock awards, accounting for 57% of the total pay in 2016.

Arbuckle also received $420K in non-equity incentive plan, $1.3M in option awards, $672.9K in salary and $12.9K in other compensation.

Rankings

In 2016, Stuart A. Arbuckle's compensation ranked 1,364th out of 14,075 executives tracked by ExecPay. In other words, Arbuckle earned more than 90.3% of executives.

ClassificationRankingPercentile
All
1,364
out of 14,075
90th
Division
Manufacturing
458
out of 5,489
92nd
Major group
Chemicals And Allied Products
124
out of 1,895
94th
Industry group
Drugs
84
out of 1,538
95th
Industry
Pharmaceutical Preparations
68
out of 1,176
94th
Source: SEC filing on April 28, 2017.

Arbuckle's colleagues

We found five more compensation records of executives who worked with Stuart A. Arbuckle at Vertex Pharmaceuticals in 2016.

2016

Jeffrey Leiden

Vertex Pharmaceuticals

Chief Executive Officer

2016

Michael Parini

Vertex Pharmaceuticals

EVP & Chief Legal and Administrative Officer

2016

Ian Smith

Vertex Pharmaceuticals

Chief Financial Officer

2016

Amit Sachdev

Vertex Pharmaceuticals

EVP & Chief Regulatory Officer

2016

David Altshuler

Vertex Pharmaceuticals

Chief Scientific Officer

News

You may also like